Jason A. Mouabbi, MD, discusses how ESR1 mutations should be monitored after each progression in hormone receptor-positive breast cancer patients and treated with elacestrant, emphasizing the importance of liquid biopsies for detection and the promising results from studies like SERENA-6 that suggest switching therapy early based on molecular progression rather than waiting for radiological evidence.